PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!
Siirry offline-tilaan Player FM avulla!
Gastrointestinal and Hematologic TEAEs Related to ADC Therapy in Gynecologic Cancers
MP3•Jakson koti
Manage episode 419469160 series 3128163
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 1.00
Valid until: 19-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
…
continue reading
Valid until: 19-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
603 jaksoa
MP3•Jakson koti
Manage episode 419469160 series 3128163
Sisällön tarjoaa ReachMD. ReachMD tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
CME credits: 1.00
Valid until: 19-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
…
continue reading
Valid until: 19-03-2025
Claim your CME credit at https://reachmd.com/programs/cme/gastrointestinal-and-hematologic-teaes-related-to-adc-therapy-in-gynecologic-cancers/18172/
"Mastering the AEs of ADCs to Unlock Their Full Potential in Breast, Lung, and Gynecologic Cancer” is a multiepisodic CME series that delves into the treatment-emergent adverse events related to antibody-drug conjugates. Join expert faculty as they assess these toxicities and provide guidance on the optimal management of these side effects. On April 5, 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. . To learn more about this approval, please visit: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2
603 jaksoa
Kaikki jaksot
×Tervetuloa Player FM:n!
Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.